Pathophysiology of immune thrombocytopenia
- 1 September 2018
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Hematology
- Vol. 25 (5), 373-381
- https://doi.org/10.1097/MOH.0000000000000447
Abstract
Purpose of reviewImmune thrombocytopenia (ITP) is a common autoimmune bleeding disorder with as of yet, no established clinical prognostic or diagnostic biomarkers. Patients frequently experience a markedly decreased quality of life and may be at risk for severe/fatal haemorrhage. Here, we address discoveries in the pathogenesis of ITP, and novel therapeutic strategies in mouse models and human patients. Consolidation of these findings should be important in providing insight to establish future prognostic protocols as well as cutting-edge therapeutics to target refractory ITP.Recent findingsIt is unknown why a significant portion of ITP patients are refractory to standard treatments. Recent findings suggest distinct heterogeneity in ITP including antibody-mediated platelet activation, Fc-independent desialylated platelet clearance, attenuation of platelet-mediated hepatic thrombopoietin generation, and decreased CD8(+) T-suppressor generation. These mechanisms may partially explain clinical observations of increased refractoriness to standard therapies targeting classical Fc-dependent pathways. Moreover, these have initiated investigations into platelet desialylation as a diagnostic/prognostic marker and therapeutic target.SummaryRecent evidence of distinct ITP pathophysiology has opened new exploratory avenues for disease management. We will discuss the utility of investigations into these mechanisms of ITP and its potential impact in our understanding of pathogenesis and future treatment strategies.Keywords
This publication has 149 references indexed in Scilit:
- Effects of Rapamycin Combined with Low Dose Prednisone in Patients with Chronic Immune ThrombocytopeniaClinical and Developmental Immunology, 2013
- The maternal immune response to fetal platelet GPIbα causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapiesJCI Insight, 2011
- Are maternal antiplatelet antibodies a prothrombotic condition leading to miscarriage?JCI Insight, 2011
- Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agentsBlood, 2010
- Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research DatabaseHaematologica, 2010
- Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpuraHaematologica, 2009
- Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C–related immunologic thrombocytopeniaBlood, 2009
- Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpuraBlood, 2008
- Structural Basis of Integrin Regulation and SignalingAnnual Review of Immunology, 2007
- T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpuraNature Medicine, 2003